These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22153572)

  • 1. Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy.
    Schmid SM; Eichholzer M; Bovey F; Myrick ME; Schötzau A; Güth U
    Breast; 2012 Aug; 21(4):487-92. PubMed ID: 22153572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer.
    Myrick ME; Schmid SM; Kilic N; Güth U
    Acta Oncol; 2012 Feb; 51(2):247-53. PubMed ID: 21985132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
    de Azambuja E; McCaskill-Stevens W; Francis P; Quinaux E; Crown JP; Vicente M; Giuliani R; Nordenskjöld B; Gutiérez J; Andersson M; Vila MM; Jakesz R; Demol J; Dewar J; Santoro A; Lluch A; Olsen S; Gelber RD; Di Leo A; Piccart-Gebhart M
    Breast Cancer Res Treat; 2010 Jan; 119(1):145-53. PubMed ID: 19731015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
    Meyerhardt JA; Tepper JE; Niedzwiecki D; Hollis DR; McCollum AD; Brady D; O'Connell MJ; Mayer RJ; Cummings B; Willett C; Macdonald JS; Benson AB; Fuchs CS
    J Clin Oncol; 2004 Feb; 22(4):648-57. PubMed ID: 14966087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle.
    Wolters R; Schwentner L; Regierer A; Wischnewsky M; Kreienberg R; Wöckel A
    Breast Cancer Res Treat; 2012 Feb; 131(3):925-31. PubMed ID: 22080246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance differences between patients with breast cancer in university and county hospitals.
    Komenaka IK; Pennington RE; Schneider BP; Hsu CH; Norton LE; Clare SE; Zork NM; Goulet RJ
    Clin Breast Cancer; 2010 Oct; 10(5):385-91. PubMed ID: 20920983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of overweight and obesity in breast cancer patients and its significance for diagnosis and clinical management: results of the Basel Breast Cancer Database 1990-2009].
    Güth U; Schmid S; Eichholzer M
    Praxis (Bern 1994); 2013 Apr; 102(8):473-80. PubMed ID: 23570924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care.
    Buist DS; Ichikawa L; Prout MN; Yood MU; Field TS; Owusu C; Geiger AM; Quinn VP; Wei F; Silliman RA
    J Clin Oncol; 2007 Aug; 25(23):3428-36. PubMed ID: 17687148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Weighing in' on screening mammography.
    Berz D; Sikov W; Colvin G; Weitzen S
    Breast Cancer Res Treat; 2009 Apr; 114(3):569-74. PubMed ID: 18491226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance and persistence of endocrine adjuvant breast cancer therapy.
    Güth U; Myrick ME; Kilic N; Eppenberger-Castori S; Schmid SM
    Breast Cancer Res Treat; 2012 Jan; 131(2):491-9. PubMed ID: 21976056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
    Dignam JJ; Polite BN; Yothers G; Raich P; Colangelo L; O'Connell MJ; Wolmark N
    J Natl Cancer Inst; 2006 Nov; 98(22):1647-54. PubMed ID: 17105987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
    Fontein DB; Nortier JW; Liefers GJ; Putter H; Meershoek-Klein Kranenbarg E; van den Bosch J; Maartense E; Rutgers EJ; van de Velde CJ
    Eur J Surg Oncol; 2012 Feb; 38(2):110-7. PubMed ID: 22172646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
    Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ
    Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excessive gestational weight gain predicts large for gestational age neonates independent of maternal body mass index.
    Ferraro ZM; Barrowman N; Prud'homme D; Walker M; Wen SW; Rodger M; Adamo KB
    J Matern Fetal Neonatal Med; 2012 May; 25(5):538-42. PubMed ID: 22081936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
    Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
    Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
    Kilic N; Myrick ME; Schmid SM; Gueth U
    Oncology; 2011; 81(3-4):151-7. PubMed ID: 22041855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
    Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
    Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S
    Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association.
    Majed B; Dozol A; Ribassin-Majed L; Senouci K; Asselain B
    Breast Cancer Res Treat; 2011 Apr; 126(3):729-38. PubMed ID: 20872242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.